Today’s podcast showcases key updates in non-Hodgkin lymphoma (NHL) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA.
First, you will hear from Gilles Salles, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, Catherine Diefenbach, MD, NYU Langone, New York, NY, and Jia Ruan, MD, PhD, Weill Cornell Medical College, New York City, NY, who discuss novel combinations being explored in the frontline setting for diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Sattva Neelapu, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, will then give updates on the use of CAR T-cells in the relapsed/refractory (R/R) setting for NHL, including follicular lymphoma (FL) and DLBCL. This will be followed by Catherine Diefenbach, MD, NYU Langone, New York, NY, and Taylor Brooks, MD, Cleveland Clinic, Cleveland, OH, who discuss the use of bispecific antibodies, and Julio Chavez, MD, Moffitt Cancer Center, Tampa, FL, who shares data on CELMoDs under investigation for the treatment of FL and DLBCL.
The post Post-ASH NHL highlights: novel combinations in the frontline setting and advancements with immunotherapy in the R/R setting appeared first on VJHemOnc.
